Aclaris Therapeutics, Inc. (ACRS) Social Stream
Aclaris Therapeutics Inc (ACRS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ACRS.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
ACRS's average price target has moved down $0 over the prior 27 weeks.
Over the past 46 weeks, ACRS's average upside potential has been 97.62%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
ACRS Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 151 days, ACRS's average broker recommendation rating improved by 0.5.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ACRS as an investment opportunity.
- Aclaris Therapeutics Inc's variance in analysts' estimates is lower than -62.2% of all US stocks.
- ACRS has a higher upside potential (average analyst target price relative to current price) than 157% of all US stocks.
- In terms of how Aclaris Therapeutics Inc fares relative to stocks in the small market cap category, note that its average analyst price target is greater than 150.7% of that group.
- Aclaris Therapeutics Inc's number of analysts covering the stock is greater than 141.76% of stocks in the small market cap category.
In the Pharmaceutical Products industry, ACIU, ACET, and ACER are the three stocks most similar to Aclaris Therapeutics Inc regarding the price target and analyst recommendation information presented here.
Make investment decisions regarding ACRS using the data that counts. Try POWR Ratings for free.